Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Feds and industry to overhaul clinical trials

Lauren Vogel
CMAJ July 08, 2014 186 (10) E345-E346; DOI: https://doi.org/10.1503/cmaj.109-4811
Lauren Vogel
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The Canadian Institutes of Health Research (CIHR) have partnered with the pharmaceutical industry to create a national centre with the aim of overhauling Canada’s clinical trials landscape. It’s a bid to reverse declining research investment in the country and pare back bureaucratic barriers to starting trials.

The Canadian Clinical Trials Coordinating Centre, announced Apr. 24, will carry out An Action Plan to Help Attract More Clinical Trials to Canada, drafted with industry in 2012.

“We’ve lost our edge in the amount of time it takes to get a trial started here,” says Jared Rhines, vice president of strategic affairs at Canada’s Research-Based Pharmaceutical Companies (Rx&D), a partner in the initiative. “Canada is competing for clinical research on a much larger global scale now, not only with China and India, but also with Spain, Brazil and the United Kingdom.”

Canadian clinical trial activity has dropped 35% in recent years — an estimated loss of $300 to $500 million per year. That decline can partly be attributed to the increasing cost and complexity of running trials in Canada, says Belinda Vandersluis, director of implementation at the new Canadian Clinical Trials Coordinating Centre.

“Clinical trial negotiations used to be quite simple and take a couple of months to complete,” she explains. “That time frame has increased to the point that it now takes 6 to 18 months to negotiate a contract between a sponsor and a single site.”

Companies seeking to conduct trials in Canada face a maze of disparate forms, processes, standards and contracts across jurisdictions and academic sites. Eligible patients can be difficult to recruit and retain in sufficient numbers, and research ethics reviews for the same protocols often have different requirements, results and turnaround times.

“This bureaucracy slows trials, results in trials not happening and creates disincentives for physicians to get involved in research,” says Dr. P.J. Devereaux, an associate professor of clinical epidemiology and biostatistics at McMaster University in Hamilton, Ontario, who runs large-scale international trials. “We need to get to a position where we all start from the same fundamental requirements and the same basic forms so that we don’t waste time and money over basically meaningless variations.”

Figure1

A new national centre will streamline forms, contracts and ethics review processes for clinical trials to attract more research investment to Canada.

Image courtesy of Alexander Raths/iStock/Thinkstock

The new centre will develop common templates for contracts, consent forms, ethics review applications; metrics to monitor clinical trial performance; a national database of patient registries; standard operating practices, training and certification for academic sites; and a clinical trials “asset map” to showcase Canada’s research resources to potential investors. It will also advocate for a national patient recruitment strategy and bigger incentives for drug companies, including longer patents on brand-name drugs.

Over the next three years, the federal government and Rx&D will each pay $750 000, while the merged Association of Canadian Academic Healthcare Organizations and Canadian Healthcare Association will provide $45 000 to kickstart the centre. Each partner is equally represented on the centre’s governing committee, and decisions will be made by consensus.

Some health policy experts question whether this government/industry model has sufficient safeguards against undue industry influence.

“Several of these measures are long overdue, but I would have liked to see serious consideration of the ethics involved in this whole enterprise, or some acknowledgement of the potential for conflicts of interest, and I don’t see attention to that,” says Trudo Lemmens, Scholl Chair in Health Law and Policy at the University of Toronto.

This seems to be part of a broader shift toward closer ties with industry, he adds, citing the controversial appointments of drug company executives to CIHR’s governing council in recent years. “More dependence on industry funding and closer collaboration with industry may make it harder for the organization to take a critical step back in the context of clinical trials.”

Others note that the 2012 action plan doesn’t address the potential downsides of some recommendations. For example, the benefits of stronger patent protection should be weighed against the economic and health costs of delaying the release of cheaper generic medicines, says Dr. Joel Lexchin, a health policy and management professor at York University in Toronto. Measures to address longstanding concerns about the concealment of clinical trial results as proprietary information are also notably missing from the plan.

However, clinical researchers contend that these concerns shouldn’t preclude partnerships with industry to attract more trials to Canada.

“There should be boundaries, as there are in any relationship, but ultimately it’s the responsibility of investigators to do right by their patients,” says Dr. Lawrence Korngut, a neurologist at the Calgary Neuromuscular Clinic in Alberta. His research includes largescale phase II and III clinical trials. “If you’re not supported by industry, there are very few places to go to get the $20 to $50 million to run these trials.”

“For patients with rare diseases, access to experimental treatments through clinical trials is the only hope they have,” he adds. “There’s a long road ahead of us and what we need to do is work together.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 186 (10)
CMAJ
Vol. 186, Issue 10
8 Jul 2014
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Feds and industry to overhaul clinical trials
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Feds and industry to overhaul clinical trials
Lauren Vogel
CMAJ Jul 2014, 186 (10) E345-E346; DOI: 10.1503/cmaj.109-4811

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Feds and industry to overhaul clinical trials
Lauren Vogel
CMAJ Jul 2014, 186 (10) E345-E346; DOI: 10.1503/cmaj.109-4811
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • Canadian Clinical Trials Coordinating Centre
  • Scopus (1)
  • Google Scholar

More in this TOC Section

  • Medical trainees warn practice permits will drive away doctors
  • Coupons for health care a sign of creeping privatization?
  • Canada’s health system is among the least green
Show more News

Similar Articles

Collections

  • Topics
    • Vaccination
    • Research methods & statistics
    • Cardiology: ischemic heart disease

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Copyright and Permissions
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2019, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire